An Observational, Practice-Based, Open Label, Feasibility Study to Observe the Efficacy and Safety of Intramuscular Administration of Stempeucel in Malaysian Patients With Critical Limb Ischemia (CLI) Due to Buerger's Disease

Status: Recruiting

Phase of Trial: Phase IV

Latest Information Update: 13 Feb 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Mesenchymal stem cell therapies (Primary)
Indications Chronic limb-threatening ischemia
Focus Therapeutic Use
Sponsors Cell Biopeutics Resources

Most Recent Events

06 Feb 2024 Status changed from not yet recruiting to recruiting.
15 May 2023 New trial record

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com

Welcome to AdisInsight